Global platelet rich plasma market expected to generate revenue of around USD 438 million by the end of 2024, growing at a CAGR of around 12.90% between 2018 and 2024. Plasma rich platelets contain a high concentration of platelets, which are suspended in plasma after centrifugation. PRP promotes the healing of soft tissues after the growth factors are released.

Sarasota, FL -- (SBWire) -- 11/15/2018 --Zion Market Research has published a new report titled "Platelet Rich Plasma Market by Type (Pure Platelet-Rich Plasma, Leukocyte-Rich Platelet-Rich Plasma, Pure Platelet-Rich Fibrin, and Leukocyte-Rich Platelet-Rich Fibrin), by Origin (Autologous PRP, Allogeneic PRP, and Homologous PRP), by Application (Orthopedics, Dermatology, Dental, Cardiac Muscle Injury, Nerve Injury, and Others), and by End-User (Hospitals & Clinics and Research Institutions): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017 – 2024". According to the report, the global platelet rich plasma market was valued at approximately USD 185 million in 2017 and is expected to generate revenue of around USD 438 million by the end of 2024, growing at a CAGR of around 12.90% between 2018 and 2024.

Request Free Sample Report @ https://www.zionmarketresearch.com/sample/platelet-rich-plasma-market

Plasma rich platelets contain a high concentration of platelets, which are suspended in plasma after centrifugation. PRP promotes the healing of soft tissues after the growth factors are released. These growth factors are released after degranulation of the platelets. The rise in the demand for cosmetic procedures, an increase in orthopedic and rheumatology disorders, and growing awareness about platelet rich plasma therapy are projected to fuel the development of the platelet rich plasma market.

Platelet rich plasma market is segmented based on type, origin, application, and end-user. Based on type, this market is divided into pure PRP, leukocyte-rich PRP, pure platelet-rich fibrin, and leukocyte-rich platelet-rich fibrin. The pure PRP is anticipated to dominate the market in the forecast timeframe, due to its rich plasma content and its usefulness in various applications.

On the basis of origin, the market for platelet rich plasma is segmented into autologous PRP, homologous PRP, and allogeneic PRP. In 2017, the autologous PRP held the largest market share. This is due to the low threat of disease transmission, cost-effectiveness, and easy production.

By application, the market is divided into cardiac muscle injury, orthopedics, dermatology, nerve injury, and others. The orthopedics segment is anticipated to lead the market for platelet rich plasma in the upcoming years. The increase in accidents causing orthopedic disorders and rise in sports injuries are mainly fueling the demand for platelet rich plasma market.

Inquiry more about this report @ https://www.zionmarketresearch.com/inquiry/platelet-rich-plasma-market

Based on end-user, the market is segmented into hospitals and clinics and research institutes. The hospitals and clinics segment is projected to dominate the platelet rich plasma market. The presence of a large patient base is contributing to the demand for platelet rich plasma in hospitals and clinics.

Europe, Latin America, North America, Asia-Pacific, and the Middle East and Africa are the regional segments of the global market for platelet rich plasma. North America is anticipated to lead the market in the forecast period, due to the increase in the number of cosmetic surgeries, rise in the number of rheumatology cases, growing awareness about PRP therapy, and rapid approval by FDA for various platelet rich plasma products. The increasing geriatric population, rise in the number of sports-related injuries, and growing investments made in the healthcare sector are fueling the growth of the European platelet rich plasma market. In the forecast period, Asia Pacific is expected to show the highest growth, due to the increase in the number of people suffering from osteoporosis. The rise in the number of accidents, growing awareness about technologically advanced PRP products, and rise in the occurrences of neurological disorders are some other factors fueling the expansion of this market in the Asia Pacific region. Latin America and the Middle East and Africa are expected to show a slow growth rate in the forecast timeframe. The rise in the prevalence of orthopedic impairments, increase in the companies' interest to invest in these regions, and growing awareness about proper treatments for disorders are anticipated to fuel the expansion of the platelet rich plasma market in these regions.

The main players involved in the global platelet rich plasma market are Cambryn Biologics LLC, Regen Lab SA, Nuo Therapeutics, Inc., Cesca Therapeutics, Inc., Grifols International S.A., Octapharma, EmCyte Corporation, AdiStem Ltd., ISTO Biologics, and BioLife Plasma Services. These companies focus on merger and acquisition to increase their sales across the world. For instance, in 2018, Grifols acquired 24 Biotest centers in the U.S. to expand its plasma collection.

Browse the full "Platelet Rich Plasma Market" report at https://www.zionmarketresearch.com/report/platelet-rich-plasma-market

This report segments the global platelet rich plasma market as follows:

Global Platelet Rich Plasma Market: Type Segment Analysis

Pure Platelet-rich Plasma
Leukocyte-rich Platelet-rich Plasma
Pure Platelet-rich Fibrin
Leukocyte-rich Platelet-rich Fibrin

Global Platelet Rich Plasma Market: Origin Segment Analysis

Allogeneic PRP
Autologous PRP
Homologous PRP

Global Platelet Rich Plasma Market: Application Segment Analysis

Orthopedics
Dermatology
Dental
Cardiac Muscle Injury
Nerve Injury
Others

Global Platelet Rich Plasma Market: End-user Segment Analysis

Hospitals & Clinics
Research Institutions

Global Platelet Rich Plasma Market: Regional Segment Analysis

North America
The U.S.
Europe
UK
France
Germany
Asia Pacific
China
Japan
India
Latin America
Brazil
The Middle East and Africa